Drug
Afatinib clinical trials
Also written BIBW 2992, Giotrif, Gilotrif and (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate).
- studies test it
- 164
- open now
- 16
- in phase 3
- 17
- first study started
- 2003
Keep track of what changes. Save the Afatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
164 studies that test it; most in 2015 (15)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 9 |
| 2010 | 8 |
| 2011 | 11 |
| 2012 | 13 |
| 2013 | 11 |
| 2014 | 8 |
| 2015 | 15 |
| 2016 | 11 |
| 2017 | 8 |
| 2018 | 8 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 52
- Phase 2
- 98
- Phase 3
- 17
- Phase 4
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 66 · Other 98
Boehringer Ingelheim (65) · West China Hospital (6) · Massachusetts General Hospital (4) · Peking University (4) · National Cancer Institute (NCI) (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · The Netherlands Cancer Institute (3) · H. Lee Moffitt Cancer Center and Research Institute (2)
Often tested with
Tested in the same studies.
Paclitaxel (8) · Palbociclib (7) · Carboplatin (6) · Nintedanib (5) · Erlotinib (5) · Dabrafenib (4) · Dasatinib (4) · Nivolumab (4)
Studies
Open first, then newest update. How each study uses Afatinib is read from its arms, and is right about nine times in ten.
Testing it · 164
- Pemigatinib + Afatinib in Advanced Refractory Solid TumorsRecruitingPhase 1Massachusetts General HospitalNCT06302621Written as Afatinib
- A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous CarcinomaRecruitingPhase 2Yale UniversityNCT02491099Written as Afatinib
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT07653451Written as Afatinib + Toripalimab
- Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingPhase 1/2Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNCT06648096Written as Afatinib
- EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingPhase 3Region SkaneNCT06486142Written as Afatinib/Dacomitinib
- Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric CancerRecruitingPhase 1/2Jeeyun LeeNCT06085755Written as Afatinib
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 1/2West China HospitalNCT06753747Written as Afatinib(30mg)
- Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR MutationsRecruitingPhase 2National University Hospital, SingaporeNCT06062823Written as Afatinib 40 MG
- Pilot Trial for Treatment of Recurrent GlioblastomaRecruitingEarly Phase 1AHS Cancer Control AlbertaNCT05432518Written as Afatinib
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingPhase 1/2China Medical University HospitalNCT06071013Written as Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
- Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNARecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT04183712Written as Afatinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Afatinib
- Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal JunctionRecruitingPhase 2AIPING ZHOUNCT05865132Written as Afatinib
- To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCCRecruitingPhase 2Peking UniversityNCT05818982Written as Afatinib
- Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung CancerRecruitingPhase 2Qingdao Central HospitalNCT05267288Written as afatinib
- Study to Evaluate the Efficacy of Afatinib in Skull Base ChordomaNot yet recruitingPhase 2Huashan HospitalNCT05519917Written as Afatinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Afatinib
- A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV VirusWithdrawnPhase 1West China HospitalNCT06741982Written as Afatinib
- Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439136Written as Afatinib Dimaleate
- Afatinib in NSCLC With HER2 MutationCompletedPhase 2ETOP IBCSG Partners FoundationNCT02369484Written as Afatinib
See all 164 studies that test Afatinib →
Given in every arm · 17 — Afatinib is usual care beside what is tested
- Primary Tumor Resection With EGFR TKI for Stage IV NSCLCRecruitingPhase 2National Taiwan University HospitalNCT05215548Written as Afatinib
- Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingPhase 1/2Mirati Therapeutics Inc.NCT03785249Written as Afatinib
- A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.CompletedPhase 2West China HospitalNCT07040956Written as Afatinib
- S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerCompletedPhase 2/3SWOG Cancer Research NetworkNCT02438722Written as Afatinib Dimaleate
- Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined CancersTerminatedPhase 2Partner Therapeutics, Inc.NCT05588609Written as Afatinib Oral Tablet
- Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck CancerCompletedPhase 1Dana-Farber Cancer InstituteNCT01783587Written as Afatinib
- Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCCWithdrawnPhase 2West China HospitalNCT06804850Written as Afatinib
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as Afatinib
- Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.CompletedPhase 1Boehringer IngelheimNCT01649271Written as afatinib
- Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to ErlotinibCompletedPhase 1Jonathan RiessNCT02364609Written as Afatinib Dimaleate
- Cambridge Brain Mets Trial 1TerminatedPhase 1/2Cambridge University Hospitals NHS Foundation TrustNCT02768337Written as Afatinib
- Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerCompletedPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT02716311Written as Afatinib
- BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLCCompletedPhase 2National Cancer Center, KoreaNCT01156545Written as BIBW 2992
- Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma MultiformCompletedPhase 1Boehringer IngelheimNCT00977431Written as BIBW2992
- Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal CancerCompletedPhase 2UNICANCERNCT01919879Written as Cetuximab + Afatinib
- Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02171754Written as BIBW 2992
- Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2CompletedPhase 1Boehringer IngelheimNCT00906698Written as BIBW 2992 low (20mg) dosage
As the comparator · 1 — what is tested is compared with Afatinib
Codes
What other systems call Afatinib · ClinicalTrials.gg INT006789
- MeSH (NLM) D000077716AfatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 41UD74L59MAFATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1430438Confirmed FDA, Wikidata
- Wikidata Q4688818afatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66940AfatinibOne source FDA
- DrugBank DB08916One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077716 | Afatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 41UD74L59M | AFATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1430438 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4688818 | afatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66940 | Afatinib | One source FDA |
| DrugBank | DB08916 | — | One source Wikidata |
Also registered as afatinib dimaleate (UNII V1T5K7RZ0B · RxNorm 1430441).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.